CABA Cabaletta Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CABA

Price (delayed)

$7.53

Market cap

$236M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.81

Enterprise value

$159.53M

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, ...

Highlights
The equity has grown by 22% from the previous quarter but it has contracted by 11% YoY
Cabaletta Bio's quick ratio has decreased by 24% QoQ and by 23% YoY
CABA's net income is down by 14% year-on-year and by 3.5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cabalettabio.com
Peers: OVID

Key stats

What are the main financial stats of CABA
Market
Shares outstanding
31.34M
Market cap
$236M
Enterprise value
$159.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$52.98M
EBITDA
-$49.29M
Free cash flow
-$48.83M
Per share
EPS
-$1.81
Free cash flow per share
-$1.68
Book value per share
$3.6
Revenue per share
$0
TBVPS
$4.03
Balance sheet
Total assets
$116.97M
Total liabilities
$12.45M
Debt
$5.14M
Equity
$104.52M
Working capital
$99.35M
Liquidity
Debt to equity
0.05
Current ratio
11.47
Quick ratio
11.23
Net debt/EBITDA
1.55
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.9%
Return on equity
-54%
Return on invested capital
-140.1%
Return on capital employed
-49.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CABA stock price

How has the Cabaletta Bio stock price performed over time
Intraday
0.8%
1 week
-7.04%
1 month
-8.39%
1 year
228.82%
YTD
-18.59%
QTD
-18.59%

Financial performance

How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$54.14M
Net income
-$52.98M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 17% YoY and by 4.7% from the previous quarter
CABA's net income is down by 14% year-on-year and by 3.5% since the previous quarter

Growth

What is Cabaletta Bio's growth rate over time

Valuation

What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
2.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's price to book (P/B) is 132% higher than its last 4 quarters average of 0.9
The equity has grown by 22% from the previous quarter but it has contracted by 11% YoY

Efficiency

How efficient is Cabaletta Bio business performance
The ROIC has soared by 99% YoY and by 21% from the previous quarter
Cabaletta Bio's ROE has decreased by 28% YoY and by 7% from the previous quarter
Cabaletta Bio's return on assets has decreased by 25% YoY and by 6% QoQ

Dividends

What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CABA.

Financial health

How did Cabaletta Bio financials performed over time
Cabaletta Bio's total liabilities has soared by 115% from the previous quarter and by 49% YoY
Cabaletta Bio's total assets has increased by 28% from the previous quarter but it has decreased by 7% YoY
CABA's debt is 95% smaller than its equity
The equity has grown by 22% from the previous quarter but it has contracted by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.